<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Nutr</journal-id><journal-id journal-id-type="publisher-id">BJN</journal-id><journal-title-group><journal-title>The British Journal of Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0007-1145</issn><issn pub-type="epub">1475-2662</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28393746</article-id><article-id pub-id-type="pmc">5426318</article-id><article-id pub-id-type="doi">10.1017/S0007114517000721</article-id><article-id pub-id-type="pii">S0007114517000721</article-id><article-id pub-id-type="publisher-id">00072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Papers</subject></subj-group><subj-group subj-group-type="section"><subject>Human and Clinical Nutrition</subject></subj-group></article-categories><title-group><article-title>Changes in serum phosphate and potassium and their effects on mortality in
malnourished African HIV-infected adults starting antiretroviral therapy and given
vitamins and minerals in lipid-based nutritional supplements: secondary analysis from the
Nutritional Support for African Adults Starting Antiretroviral Therapy (NUSTART) trial</article-title><alt-title alt-title-type="left-running">A. M. Rehman <italic>et al</italic>.</alt-title><alt-title alt-title-type="right-running">Serum electrolytes in African HIV
patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9967-5822</contrib-id><name><surname>Rehman</surname><given-names>Andrea Mary</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Woodd</surname><given-names>Susannah Louise</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3551-9710</contrib-id><name><surname>Heimburger</surname><given-names>Douglas Corbett</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Koethe</surname><given-names>John Robert</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2848-2940</contrib-id><name><surname>Friis</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>PrayGod</surname><given-names>George</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kasonka</surname><given-names>Lackson</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Filteau</surname><given-names>Suzanne</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>London School of Hygiene &#x00026; Tropical Medicine</institution>,
<addr-line>London WC1E 7HT</addr-line>, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Vanderbilt University Medical Center</institution>, <addr-line>Nashville, TN
37232</addr-line>, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>University of Copenhagen</institution>, <addr-line>1958 Copenhagen</addr-line>,
<country>Denmark</country></aff><aff id="aff4"><label>4</label><addr-line>Mwanza Research Centre</addr-line>, <institution>National Institute for Medical
Research</institution>, <addr-line>Mwanza</addr-line>, <country>Tanzania</country></aff><aff id="aff5"><label>5</label><institution>University Teaching Hospital</institution>, <addr-line>Lusaka</addr-line>,
<country>Zambia</country></aff><aff id="aff6"><label>6</label><addr-line>Barts and the London School of Medicine</addr-line>, <institution>Queen Mary
University of London</institution>, <addr-line>London E1 2AT</addr-line>,
<country>UK</country></aff><author-notes><corresp id="cor1"><label>*</label><bold>Corresponding author:</bold> Dr A. M. Rehman, email <email>Andrea.Rehman@lshtm.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>3</month><year>2017</year></pub-date><volume>117</volume><issue>6</issue><fpage>814</fpage><lpage>821</lpage><history><date date-type="received"><day>08</day><month>9</month><year>2016</year></date><date date-type="rev-recd"><day>03</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>03</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Authors 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>The Authors</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted
re-use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0007114517000721a.pdf"/><abstract abstract-type="normal"><p>Malnourished HIV-infected patients starting antiretroviral therapy (ART) are at high risk
of early mortality, some of which may be attributed to altered electrolyte metabolism. We
used data from a randomised controlled trial of electrolyte-enriched lipid-based
nutritional supplements to assess the association of baseline and time-varying serum
phosphate and K concentrations with mortality within the first 12 weeks after starting
ART. Baseline phosphate results were available from 1764 patients and there were 9096
subsequent serum phosphate measurements, a median of 6 per patient. For serum K there were
1701 baseline and 8773 subsequent measures, a median of 6 per patient. Abnormally high or
low serum phosphate was more common than high or low serum K. Controlling for other
factors found to affect mortality in this cohort, low phosphate which had not changed from
the previous time interval was associated with increased mortality; the same was not true
for high phosphate or for high or low K. Both increases and decreases in serum
electrolytes from the previous time interval were generally associated with increased
mortality, particularly in the electrolyte-supplemented group. The results suggest that
changes in serum electrolytes, largely irrespective of the starting point and the
direction of change, were more strongly associated with mortality than were absolute
electrolyte levels. Although K and phosphate are required for tissue deposition during
recovery from malnutrition, further studies are needed to determine whether specific
supplements exacerbate physiologically adverse shifts in electrolyte levels during
nutritional rehabilitation of ill malnourished HIV patients.</p></abstract><kwd-group><title>Key words</title><kwd>Potassium</kwd><kwd>Phosphate</kwd><kwd>HIV</kwd><kwd>Antiretroviral therapy</kwd><kwd>Malnutrition</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><compound-kwd><compound-kwd-part content-type="abbrev">ART</compound-kwd-part><compound-kwd-part content-type="expansion">antiretroviral therapy</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">DAIDA</compound-kwd-part><compound-kwd-part content-type="expansion">Division of AIDS</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">IQR</compound-kwd-part><compound-kwd-part content-type="expansion">interquartile range</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">LNS</compound-kwd-part><compound-kwd-part content-type="expansion">lipid-based nutritional
supplement</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">LNS-VM</compound-kwd-part><compound-kwd-part content-type="expansion">lipid-based nutritional supplements fortified
with vitamins and minerals</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">NUSTART</compound-kwd-part><compound-kwd-part content-type="expansion">Nutritional Support for African Adults
Starting Antiretroviral Therapy</compound-kwd-part></compound-kwd></kwd-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="8"/></counts></article-meta></front><body><p>The last decade has seen great advances in expanding access to antiretroviral therapy (ART)
for HIV-infected Africans. However, poor survival in the first few months of ART remains a
major concern and undernutrition is a consistent risk factor for this early mortality<sup>(</sup>
<xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>. Malnutrition in these studies has usually been indicated by low BMI but
mortality may result from metabolic alterations associated with low BMI, not simply from loss
of lean or fat tissue<sup>(</sup>
<xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup>. Severe malnutrition is associated with disordered metabolism of Na, K, P and
Mg<sup>(</sup>
<xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>. Low serum phosphate is often present among malnourished Africans starting ART
and is an independent risk factor for early mortality<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>.</p><p>We conducted the Nutritional Support for African Adults Starting Antiretroviral Therapy
(NUSTART) trial to test if a high content of vitamins and minerals in a lipid-based
nutritional supplement (LNS) would decrease mortality of malnourished adults referred for
ART<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. The intervention used a two-stage dietary protocol based on established methods
for managing malnutrition among young children whereby there is a stabilisation phase
providing micronutrients and electrolytes but only modest energy content followed by a
rehabilitation phase with higher energy content in order to permit weight gain<sup>(</sup>
<xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>. We focused on micronutrients because of their potential benefit for HIV
patients,<sup>(</sup>
<xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup> and on electrolytes, both because of their importance in treating
malnutrition<sup>(</sup>
<xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup> and because low phosphate in HIV patients starting ART may be similar to a
potentially dangerous refeeding syndrome<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>.</p><p>In the NUSTART trial, the addition of a vitamin and mineral fortificant to the LNS (LNS-VM)
did not decrease mortality within the first 12 weeks of ART compared with the unfortified LNS
but did result in increases in some anthropometric measures and CD4 count (adjusted
improvement of 25 cells/&#x000b5;l)<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="ref10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup>. The LNS-VM was also associated with increased incidence of both high phosphate
(&#x0003e;1&#x000b7;45 mmol/l; rate ratio (RR) 1&#x000b7;23 compared with LNS) and high K (&#x0003e;5&#x000b7;5 mmol/l;
RR 1&#x000b7;6), and decreased incidence of low phosphate (&#x0003c;0&#x000b7;65 mmol/l; RR 0&#x000b7;73)<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. Previous work from our group has shown increased mortality associated with low
serum phosphate (17 % increase/0&#x000b7;1 mmol/l increase)<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>; however, analysis of NUSTART patients found significant nonlinear associations
between baseline electrolytes and survival and before starting ART, high, rather than low,
phosphate appeared to carry a greater risk of death<sup>(</sup>
<xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup>. In addition, we observed that the LNS-VM decreased renal wasting of K and
phosphate but not Mg<sup>(</sup>
<xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>. In view of the effects of the LNS-VM intervention on electrolyte metabolism and
on the association of electrolyte metabolism with mortality, we conducted a secondary analysis
of NUSTART data. We performed detailed time course analysis of the effects of the intervention
and its associated time-varying consequences on electrolyte levels and on the changes in
electrolyte levels in relation to mortality in the trial.</p><sec sec-type="methods" id="sec1"><title>Methods</title><sec id="sec1-1" sec-type="general"><title>Study design and intervention</title><p>NUSTART was an individually randomised, controlled, two-site, two-arm, phase III trial
comparing LNS (Nutriset) either with (LNS-VM) or without (LNS) high levels of vitamins and
minerals among participants who were HIV-positive and malnourished. The trial design,
detailed intervention and primary findings have been reported previously<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. The intervention was given at two graduated energetic doses mimicking
nutritional management of malnourished children<sup>(</sup>
<xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>; daily vitamin and mineral doses were the same in both the low-energy period
given from referral to ART until 2 weeks after starting ART and the higher energy period
given from weeks 2 to 6 of ART. Follow-up without supplementation continued until week 12
of ART. Varying actual ART start dates resulted in varied pre-ART durations of LNS or
LNS-VM consumption with the median and mode being 3 weeks. The daily phosphate intake from
the fortified LNS-VM was 38&#x02013;47 mmol (according to the manufacturer&#x02019;s analyses; the range
is due to variability in product batches); for comparison, the UK upper reference nutrient
intake (RNI) is 17&#x000b7;5 mmol/d for adults<sup>(</sup>
<xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. The daily K intake from LNS-VM was 30&#x02013;32 mmol; the UK RNI for adults is 90
mmol/d. The trial was registered at PACTR201106000300631.</p></sec><sec id="sec1-2" sec-type="general"><title>Setting and participants</title><p>The trial was conducted between August 2011 and December 2013 at the National Institute
for Medical Research (NIMR), Mwanza, Tanzania and the University Teaching Hospital,
Lusaka, Zambia. Participants were recruited from HIV clinics near the two trial sites.
Eligible participants had BMI &#x0003c;18&#x000b7;5 kg/m<sup>2</sup>, were ART naive (except for
previous short course regimens used to prevent mother to child HIV transmission), needed
to start ART as determined by CD4 count &#x0003c;350 cells/&#x003bc;l or WHO stage 3 or 4<sup>(</sup>
<xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>, were at least 18 years old, willing to undertake intensive follow-up in the
study clinics, and providing informed consent. Participants were ineligible if
participating in a potentially conflicting research study or self-reported a
pregnancy.</p></sec><sec id="sec1-3" sec-type="general"><title>Randomisation and masking</title><p>The statistician member of the independent data safety and monitoring committee generated
the randomisation list. The list was computer generated in blocks of sixteen and
stratified by country. Clinic pharmacists labelled the packets of LNS-VM and LNS with
study ID numbers as packages were dispensed. Clinic nurses who were blinded to the
randomisation list assigned sequential (within site) ID numbers.</p></sec><sec id="sec1-4" sec-type="general"><title>Follow-up and data management</title><p>Patients were seen weekly from recruitment until the ART initiation visit, then at 2, 4,
6, 8, and 12 weeks after starting ART. Participants could also come for unscheduled visits
at any time.</p><p>At each visit, including unscheduled ones, medical and other examinations were
conducted<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup> and blood samples were collected for electrolyte assays. For ethical reasons,
we provided specific electrolyte supplements to participants with low electrolyte values.
Phosphate tablets (97 mmol/d for 7 d) were supplied to thirty-seven participants and K
tablets (48 mmol/d for 7 d) to nine participants. One participant in Lusaka received
intravenous K (40 mmol over 8 h).</p></sec><sec id="sec1-5" sec-type="general"><title>Laboratory analysis</title><p>In Lusaka serum phosphate was measured spectrochemically on a Pointe 180 analyser (Pointe
Scientific). Sample results were accepted only from runs for which the external quality
control (QC) sample from the same supplier was within expected range; for unacceptable
runs, samples were reanalysed where possible or omitted if not. Inter-assay CV for this
external QC was 7 %. In Mwanza serum phosphate was measured in an external laboratory
(Bugando Medical Centre) using a Roche COBAS Integra 400 analyser (Roche Molecular
Diagnostics). Serum K was measured by optical emission using Perkin Elmer Optima 7000 ICP
(Perkin Elmer). An external QC (Seronorm; Alere) was run each day and values were within
expected limits at both sites. Inter-assay CV for K were 5 % in Mwanza and 6 % in Lusaka.</p><p>Cut-offs for low (&#x0003c;0&#x000b7;65 mmol/l) serum phosphate and low (&#x0003c;2&#x000b7;5 mmol/l) or
high (&#x0003e;6&#x000b7;5 mmol/l) serum K levels were set according to the US National Institutes
of Health, Division of AIDS (DAIDS<sup>(</sup>
<xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>) grades 3 and 4. DAIDS does not set high ranges for phosphate so we
considered as above normal limits if &#x0003e;1&#x000b7;45 mmol/l and below normal limits if
&#x0003c;0&#x000b7;87 mmol/l<sup>(</sup>
<xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup>; for comparison we also looked at any K above, &#x0003e;5&#x000b7;5 mmol/l, or below,
&#x0003c;3&#x000b7;5 mmol/l, normal limits<sup>(</sup>
<xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup> which were equivalent to grades 1 or 2 DAIDS.</p></sec><sec id="sec1-6" sec-type="general"><title>Statistical analysis and outcomes</title><p>Data were double entered into OpenClinica data management system in Lusaka and into CSPro
4.1 and stored in MySQL databases in Mwanza. Analyses were conducted in STATA version
14.1.</p><p>Electrolyte levels at the end of follow-up (12 weeks post-ART) were analysed as
continuous variables. Means were compared between treatment arms using <italic>t</italic>
tests and linear regression adjusting for baseline values. Comparisons at the end of
follow-up, by definition, used the subset of patients who survived and attended the
12-week visit within 14 d of the scheduled date (i.e. up to 14 weeks post-ART) as decided
<italic>a priori</italic>. However, we also wanted to investigate treatment effects
using all measured data, including data from patients who died or were lost to follow-up
until the point they were lost from the study. We used piecewise mixed-effects cubic
regression models with the time axis split at the date of starting ART. Random intercepts
and random linear slopes were incorporated into the model. This model fitted two lines per
person with differing slopes, restricting the lines to join at the date of starting ART.
<italic>P</italic> values provide evidence of whether the shape of curves differed by
treatment arm. For presentation, marginal predictions are graphed and are based on the
median time, 21 d, spent before starting ART.</p><p>Knowing that LNS-VM was associated with increased incidence of high electrolyte values,
and that risk of death before starting ART appeared higher with increasing levels of
baseline serum phosphate<sup>(</sup>
<xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup>, we sought to examine the effect of the intervention on mortality allowing
for the time-varying measurements of electrolyte values. Time was split into 4-week bands
and also split pre- and post-starting ART, and controlled for in the analysis.
Participants with electrolytes measured only once (<italic>n</italic> 156 for phosphate;
<italic>n</italic> 104 for K) were excluded because time changes could not be
determined, and those missing ART start date (<italic>n</italic> 31) were excluded from
analysis because the split could not be performed. Participants were censored at 14 weeks
after starting ART, at their last visit if they were lost to follow-up or withdrew, or at
10 weeks after recruitment for the 114 participants who had not yet started ART by this
point. We used time-to-event shared frailty Poisson regression models to estimate the
effect of treatment arm on mortality using hazard ratios, both unadjusted and adjusted for
factors associated with mortality. The current (and time changing) value of the
electrolyte was categorised into tertiles of high, middle or low. Standardised changes
from the previous value, to control for varying intervals between visits, were categorised
into increase, no change or decrease; for K increase or decrease was defined as
&#x0003e;0&#x000b7;03 mmol/d and for phosphate it was defined as &#x0003e;0&#x000b7;02 mmol/d. These two
variables were incorporated into models as main effects and additionally tested for
interaction. When interaction was present, current level and change from previous level
were combined to form a categorical variable with nine levels. In either case, these
variables were allowed to vary over time in the model.</p></sec><sec id="sec1-7" sec-type="general"><title>Sample size</title><p>Recruitment to the trial was stopped early, following advice from the trial Data Safety
and Monitoring Board, because a higher than expected mortality rate (not related to the
intervention) meant we already had sufficient power for the primary outcome of
mortality<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. The 1815 participants who were enrolled in the trial gave 90 % power to
detect a difference of 30 % between trial arms in the primary outcome of mortality. The
800 participants with electrolyte values measured at 12 weeks after initiating ART gave 80
% power to detect a difference of 0&#x000b7;20 mmol/l between trial arms.</p></sec><sec id="sec2" sec-type="general"><title>Ethics</title><p>The study was conducted according to the guidelines laid down in the Declaration of
Helsinki and all procedures involving human participants were approved by the ethics
committee of the London School of Hygiene and Tropical Medicine, the Medical Research
coordinating committee of NIMR, Tanzania and the University of Zambia Biomedical Research
Ethics Committee. Written or thumbprint consent was obtained from all participants.
Patients received medical care from local health services according to national
guidelines.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><p>Participants were comparable at baseline between trial arms (<xref ref-type="table" rid="tab1">Table 1</xref> for participants with phosphate data and the online
Supplementary Table S1 for the slightly different number of participants with K data). Of
1815 participants, 1764 (97 %) had baseline serum phosphate data and 1710 (94 %) had
baseline K data (<xref ref-type="table" rid="tab2">Table 2</xref>). Phosphate at baseline
was above normal levels (&#x0003e;1&#x000b7;45 mmol/l) in one-fifth of participants and below normal
(&#x0003c;0&#x000b7;87 mmol/l) in 14 %; K was above normal levels (&#x0003e;5&#x000b7;5 mmol/l) in 3 % and
below normal (&#x0003c;3&#x000b7;5 mmol/l) in 15 % of participants (<xref ref-type="table" rid="tab2">Table 2</xref>). Only 3&#x000b7;4 % had low levels of both K (&#x0003c;3&#x000b7;5 mmol/l) and phosphate
(&#x0003c;0&#x000b7;87 mmol/l) at baseline.<table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of patients included in the evaluation of the effect of
Nutritional Support for African Adults Starting Antiretroviral Therapy intervention on
serum phosphate (Numbers and percentages; mean values and standard deviations)</p></caption><alternatives><graphic xlink:href="S0007114517000721_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">LNS (<italic>n</italic> 883)</th><th align="center" rowspan="1" colspan="2">LNS-VM (<italic>n</italic> 898)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">
<sc>%</sc>
</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">
<sc>%</sc>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="5">Age (years)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Mean</td><td align="center" rowspan="1" colspan="2">35&#x000b7;8</td><td align="center" rowspan="1" colspan="2">35&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</td><td align="center" rowspan="1" colspan="2">9&#x000b7;44</td><td align="center" rowspan="1" colspan="2">9&#x000b7;33</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="char" char="." rowspan="1" colspan="1">445</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">50&#x000b7;4</td><td align="char" char="." rowspan="1" colspan="1">437</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">48&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">On tuberculosis treatment*</td><td align="char" char="." rowspan="1" colspan="1">129</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;6</td><td align="char" char="." rowspan="1" colspan="1">173</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">19&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="5">Baseline CD4 count (cells/&#x000b5;l)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Mean</td><td align="center" rowspan="1" colspan="2">140&#x000b7;0</td><td align="center" rowspan="1" colspan="2">135&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</td><td align="center" rowspan="1" colspan="2">103&#x000b7;3</td><td align="center" rowspan="1" colspan="2">96&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 count &#x0003c;100 (cells/&#x000b5;l)</td><td align="char" char="." rowspan="1" colspan="1">383</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">43&#x000b7;4</td><td align="char" char="." rowspan="1" colspan="1">385</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">42&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI &#x0003c;17 (kg/m<sup>2</sup>)</td><td align="char" char="." rowspan="1" colspan="1">523</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">59&#x000b7;2</td><td align="char" char="." rowspan="1" colspan="1">528</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">58&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="5">Social economic status</td></tr><tr><td align="left" rowspan="1" colspan="1"> Lowest</td><td align="char" char="." rowspan="1" colspan="1">193</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">21&#x000b7;9</td><td align="char" char="." rowspan="1" colspan="1">166</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1"> Low</td><td align="char" char="." rowspan="1" colspan="1">184</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">181</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;2</td></tr><tr><td align="left" rowspan="1" colspan="1"> Middle</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;1</td><td align="char" char="." rowspan="1" colspan="1">194</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">21&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1"> High</td><td align="char" char="." rowspan="1" colspan="1">180</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;4</td><td align="char" char="." rowspan="1" colspan="1">170</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1"> Highest</td><td align="char" char="." rowspan="1" colspan="1">166</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">187</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="5">Marital status*</td></tr><tr><td align="left" rowspan="1" colspan="1"> Married</td><td align="char" char="." rowspan="1" colspan="1">430</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">48&#x000b7;7</td><td align="char" char="." rowspan="1" colspan="1">411</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">45&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1"> Widow/widower</td><td align="char" char="." rowspan="1" colspan="1">104</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">11&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">95</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">10&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1"> Divorced/separated</td><td align="char" char="." rowspan="1" colspan="1">237</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">26&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">261</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">29&#x000b7;1</td></tr><tr><td align="left" rowspan="1" colspan="1"> Single</td><td align="char" char="." rowspan="1" colspan="1">108</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">12&#x000b7;2</td><td align="char" char="." rowspan="1" colspan="1">129</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1"> Lives with partner</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td align="left" rowspan="1" colspan="1">Occupation*</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Salaried</td><td align="char" char="." rowspan="1" colspan="1">135</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">15&#x000b7;3</td><td align="char" char="." rowspan="1" colspan="1">130</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1"> Self-employed</td><td align="char" char="." rowspan="1" colspan="1">454</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">51&#x000b7;4</td><td align="char" char="." rowspan="1" colspan="1">475</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">52&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1"> Housewife</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">10&#x000b7;5</td><td align="char" char="." rowspan="1" colspan="1">84</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">9&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1"> Student</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;0</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1"> Unemployed</td><td align="char" char="." rowspan="1" colspan="1">191</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">21&#x000b7;6</td><td align="char" char="." rowspan="1" colspan="1">200</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">22&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="5">Education level*</td></tr><tr><td align="left" rowspan="1" colspan="1"> None</td><td align="char" char="." rowspan="1" colspan="1">167</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;9</td><td align="char" char="." rowspan="1" colspan="1">168</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1"> Primary</td><td align="char" char="." rowspan="1" colspan="1">508</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">57&#x000b7;5</td><td align="char" char="." rowspan="1" colspan="1">518</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">57&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1"> Secondary</td><td align="char" char="." rowspan="1" colspan="1">184</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">188</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1"> University/tertiary</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;6</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="5">Study site</td></tr><tr><td align="left" rowspan="1" colspan="1"> Lusaka</td><td align="char" char="." rowspan="1" colspan="1">540</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;2</td><td align="char" char="." rowspan="1" colspan="1">552</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1"> Mwanza</td><td align="char" char="." rowspan="1" colspan="1">343</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">38&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">346</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">38&#x000b7;5</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>LNS, lipid-based nutritional supplement; LNS-VM, lipid-based nutritional supplement
with added vitamins and minerals.</p></fn><fn id="tab1fn1"><label>*</label><p>Missing values for: on tuberculosis treatment, 7 (0&#x000b7;8 %) LNS arm, 6 (0&#x000b7;7 %) LNS-VM
arm; marital status: 1 (0&#x000b7;1 %) LNS arm; occupation: 1 (0&#x000b7;1 %) LNS arm; education
level: 1 (0&#x000b7;1 %) LNS arm.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Serum phosphate and potassium values at baseline among patients randomised to
lipid-based nutritional supplement (LNS) or lipid-based nutritional supplement with
added vitamins and minerals (LNS-VM) (Mean values and standard deviations; numbers and
percentages)</p></caption><alternatives><graphic xlink:href="S0007114517000721_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">LNS-VM</th><th align="center" rowspan="1" colspan="2">LNS</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
<xref ref-type="fn" rid="tab2fn1">*</xref>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
<xref ref-type="fn" rid="tab2fn1">*</xref>
</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Serum phosphate (mmol/l)</td><td align="char" char="." rowspan="1" colspan="1">888</td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">876</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Mean</td><td align="center" rowspan="1" colspan="2">1&#x000b7;24</td><td align="center" rowspan="1" colspan="2">1&#x000b7;24</td></tr><tr><td align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</td><td align="center" rowspan="1" colspan="2">0&#x000b7;41</td><td align="center" rowspan="1" colspan="2">0&#x000b7;37</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003c;0&#x000b7;65 mmol/l<xref ref-type="fn" rid="tab2fn2">&#x02020;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003c;0&#x000b7;87 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">113</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">83</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003e;1&#x000b7;45 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">177</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">169</td><td align="char" char="." rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1"> Missing</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum K (mmol/l)</td><td align="char" char="." rowspan="1" colspan="1">861</td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">849</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Mean</td><td align="center" rowspan="1" colspan="2">4&#x000b7;14</td><td align="center" rowspan="1" colspan="2">4&#x000b7;09</td></tr><tr><td align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</td><td align="center" rowspan="1" colspan="2">0&#x000b7;73</td><td align="center" rowspan="1" colspan="2">0&#x000b7;72</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003c;2&#x000b7;5 mmol/l<xref ref-type="fn" rid="tab2fn2">&#x02020;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003c;3&#x000b7;5 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">133</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">141</td><td align="char" char="." rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003e;5&#x000b7;5 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003e;6&#x000b7;5 mmol/l<xref ref-type="fn" rid="tab2fn2">&#x02020;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="center" char="." rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td align="left" rowspan="1" colspan="1"> Missing</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tab2fn1"><label>*</label><p>Total enrolled in the trial were: LNS-VM arm, <italic>n</italic> 914; LNS arm,
<italic>n</italic> 901.</p></fn><fn id="tab2fn2"><label>&#x02020;</label><p>Values from Division of AIDS grades 3 or 4 adverse events<sup>(</sup>
<xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>.</p></fn><fn id="tab2fn3"><label>&#x02021;</label><p>Values below or above normal range<sup>(</sup>
<xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup>.</p></fn></table-wrap-foot></table-wrap>
</p><p>Up to 14 weeks after starting ART, there were 9096 subsequent phosphate results in 1608
participants, median 6 (interquartile range (IQR) 3&#x02013;8) per patient, and 8773 subsequent K
results in 1606 participants, median 6 (IQR 3&#x02013;7) per patient, with comparable numbers of
observations in each trial arm. Above normal phosphate (&#x0003e;1&#x000b7;45 mmol/l) was the most
commonly occurring abnormal electrolyte result (<xref ref-type="table" rid="tab3">Table
3</xref>). Episodes of above normal phosphate measured on consecutive occasions, that is
weekly, every 2 or every 4 weeks, depending on the time before or after starting ART,
occurred in 368 (204 from LNS-VM arm) participants for a median episode length of 14 (IQR
7&#x02013;28) d. Episodes of low phosphate (&#x0003c;0&#x000b7;65 mmol/l; DAIDS grades 3 and 4) measured on
consecutive occasions occurred in twenty-eight participants for a median episode length of
14 (IQR 7&#x02013;17&#x000b7;5) d. There were no occasions where high K (&#x0003e;6&#x000b7;5 mmol/l; DAIDS grades 3
and 4) was measured on consecutive occasions. Seven participants experienced episodes of K
remaining above normal, 5&#x000b7;5 mmol/l (equivalent to DAIDS grades 1 and 2), for a median of 7
(IQR 7&#x02013;14) d and eleven participants had low K (&#x0003c;2&#x000b7;5 mmol/l; DAIDS grades 3 and 4)
for a median of 14 (IQR 7&#x02013;38) d.<table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Abnormal serum electrolyte values over the study period by trial arm and total in
study (Numbers of measurements (<italic>N</italic>
<sub>m</sub>) and number of participants (<italic>N</italic>
<sub>p</sub>))</p></caption><alternatives><graphic xlink:href="S0007114517000721_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="4">Pre-ART<xref ref-type="fn" rid="tab3fn1">*</xref>
</th><th align="center" rowspan="1" colspan="6">Post-ART</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">Total</th><th align="center" rowspan="1" colspan="2">Post baseline to 21 d</th><th align="center" rowspan="1" colspan="2">&#x0003e;21 d</th><th align="center" rowspan="1" colspan="2">ART to 14 d after ART</th><th align="center" rowspan="1" colspan="2">15&#x02013;42 d after ART</th><th align="center" rowspan="1" colspan="2">43&#x02013;98 d after ART<xref ref-type="fn" rid="tab3fn2">&#x02020;</xref>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Adverse event or abnormality</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>m</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>p</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>m</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>p</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>m</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>p</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>m</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>p</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>m</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>p</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>m</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
<sub>p</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="13">Phosphate &#x0003c;0&#x000b7;65 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS-VM</td><td align="char" char="." rowspan="1" colspan="1">106</td><td align="char" char="." rowspan="1" colspan="1">87</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS</td><td align="char" char="." rowspan="1" colspan="1">137</td><td align="char" char="." rowspan="1" colspan="1">113</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">37</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="13">Phosphate &#x0003e;1&#x000b7;45 mmol/l<xref ref-type="fn" rid="tab3fn4">&#x000a7;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS-VM</td><td align="char" char="." rowspan="1" colspan="1">1081</td><td align="char" char="." rowspan="1" colspan="1">514</td><td align="char" char="." rowspan="1" colspan="1">353</td><td align="char" char="." rowspan="1" colspan="1">194</td><td align="char" char="." rowspan="1" colspan="1">89</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">207</td><td align="char" char="." rowspan="1" colspan="1">111</td><td align="char" char="." rowspan="1" colspan="1">204</td><td align="char" char="." rowspan="1" colspan="1">85</td><td align="char" char="." rowspan="1" colspan="1">228</td><td align="char" char="." rowspan="1" colspan="1">96</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS</td><td align="char" char="." rowspan="1" colspan="1">834</td><td align="char" char="." rowspan="1" colspan="1">432</td><td align="char" char="." rowspan="1" colspan="1">227</td><td align="char" char="." rowspan="1" colspan="1">130</td><td align="char" char="." rowspan="1" colspan="1">65</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">142</td><td align="char" char="." rowspan="1" colspan="1">69</td><td align="char" char="." rowspan="1" colspan="1">177</td><td align="char" char="." rowspan="1" colspan="1">86</td><td align="char" char="." rowspan="1" colspan="1">223</td><td align="char" char="." rowspan="1" colspan="1">122</td></tr><tr><td align="left" rowspan="1" colspan="13">
<italic>n</italic> in study</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS-VM</td><td align="char" char="." rowspan="1" colspan="1">4717</td><td align="char" char="." rowspan="1" colspan="1">816</td><td align="char" char="." rowspan="1" colspan="1">1285</td><td align="char" char="." rowspan="1" colspan="1">716</td><td align="char" char="." rowspan="1" colspan="1">389</td><td align="char" char="." rowspan="1" colspan="1">218</td><td align="char" char="." rowspan="1" colspan="1">980</td><td align="char" char="." rowspan="1" colspan="1">623</td><td align="char" char="." rowspan="1" colspan="1">1008</td><td align="char" char="." rowspan="1" colspan="1">569</td><td align="char" char="." rowspan="1" colspan="1">1055</td><td align="char" char="." rowspan="1" colspan="1">525</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS</td><td align="char" char="." rowspan="1" colspan="1">4379</td><td align="char" char="." rowspan="1" colspan="1">792</td><td align="char" char="." rowspan="1" colspan="1">1232</td><td align="char" char="." rowspan="1" colspan="1">701</td><td align="char" char="." rowspan="1" colspan="1">284</td><td align="char" char="." rowspan="1" colspan="1">170</td><td align="char" char="." rowspan="1" colspan="1">971</td><td align="char" char="." rowspan="1" colspan="1">598</td><td align="char" char="." rowspan="1" colspan="1">935</td><td align="char" char="." rowspan="1" colspan="1">538</td><td align="char" char="." rowspan="1" colspan="1">957</td><td align="char" char="." rowspan="1" colspan="1">491</td></tr><tr><td align="left" rowspan="1" colspan="13">K &#x0003c;2&#x000b7;5 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS-VM</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="13">K &#x0003e;6&#x000b7;5 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS-VM</td><td align="char" char="." rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS</td><td align="char" char="." rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="13">K &#x0003e;5&#x000b7;5 mmol/l<xref ref-type="fn" rid="tab3fn3">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS-VM</td><td align="char" char="." rowspan="1" colspan="1">132</td><td align="char" char="." rowspan="1" colspan="1">114</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="char" char="." rowspan="1" colspan="1">71</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="13">
<italic>n</italic> in study</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS-VM</td><td align="char" char="." rowspan="1" colspan="1">4542</td><td align="char" char="." rowspan="1" colspan="1">811</td><td align="char" char="." rowspan="1" colspan="1">1249</td><td align="char" char="." rowspan="1" colspan="1">704</td><td align="char" char="." rowspan="1" colspan="1">368</td><td align="char" char="." rowspan="1" colspan="1">213</td><td align="char" char="." rowspan="1" colspan="1">949</td><td align="char" char="." rowspan="1" colspan="1">597</td><td align="char" char="." rowspan="1" colspan="1">979</td><td align="char" char="." rowspan="1" colspan="1">557</td><td align="char" char="." rowspan="1" colspan="1">997</td><td align="char" char="." rowspan="1" colspan="1">523</td></tr><tr><td align="left" rowspan="1" colspan="1"> LNS</td><td align="char" char="." rowspan="1" colspan="1">4231</td><td align="char" char="." rowspan="1" colspan="1">795</td><td align="char" char="." rowspan="1" colspan="1">1203</td><td align="char" char="." rowspan="1" colspan="1">693</td><td align="char" char="." rowspan="1" colspan="1">271</td><td align="char" char="." rowspan="1" colspan="1">166</td><td align="char" char="." rowspan="1" colspan="1">939</td><td align="char" char="." rowspan="1" colspan="1">578</td><td align="char" char="." rowspan="1" colspan="1">908</td><td align="char" char="." rowspan="1" colspan="1">526</td><td align="char" char="." rowspan="1" colspan="1">910</td><td align="char" char="." rowspan="1" colspan="1">487</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ART, antiretroviral therapy; LNS, lipid-based nutritional supplement; LNS-VM,
lipid-based nutritional supplements fortified with vitamins and minerals.</p></fn><fn id="tab3fn1"><label>*</label><p>Individuals varied in the time spent in the pre-ART period, median 3 (interquartile
range 2&#x000b7;1&#x02013;4&#x000b7;7) weeks.</p></fn><fn id="tab3fn2"><label>&#x02020;</label><p>This period was after supplementation ended.</p></fn><fn id="tab3fn3"><label>&#x02021;</label><p>Division of AIDS grades 3 or 4<sup>(</sup>
<xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>.</p></fn><fn id="tab3fn4"><label>&#x000a7;</label><p>Above normal limits<sup>(</sup>
<xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup>.</p></fn></table-wrap-foot></table-wrap>
</p><p>At the end of follow-up, 6 weeks after discontinuation of the study supplement, there was
no evidence of a difference between trial arms in mean serum phosphate (overall mean 1&#x000b7;25
(<sc>sd</sc> 0&#x000b7;35) mmol/l), adjusted difference 0&#x000b7;03 (95 % CI &#x02212;0&#x000b7;02, 0&#x000b7;08,
<italic>P</italic>=0&#x000b7;24, <italic>n</italic> 798) or mean serum K (overall mean 4&#x000b7;13
(<sc>sd</sc> 0&#x000b7;64) mmol/l), adjusted difference 0&#x000b7;002 (95 % CI &#x02212;0&#x000b7;10, 0&#x000b7;10,
<italic>P</italic>=0&#x000b7;97, <italic>n</italic> 754). Participants who had remained in the study
and had electrolytes measured at the end of follow-up were older, more likely to be female,
be on tuberculosis treatment at baseline, had higher socio-economic status, higher baseline
BMI, higher baseline CD4 count and were less likely to be divorced; for having a phosphate
measurement they were also more likely to be Zambian (online Supplementary Tables S2 and
S3).</p><p>
<xref ref-type="fig" rid="fig1">Fig. 1</xref> shows electrolyte changes over time for
patients who started ART at the median of 3 weeks after referral for treatment. Similar
figures for participants who survived until the end of the study are shown in the online
Supplementary Fig. S1 and S2, and for those starting ART 1, 2 or 4 weeks after referral are
shown in the online Supplementary Fig. S3 and S4. There was strong evidence that changes in
phosphate and K over time differed by trial arm; <italic>P</italic> values for differences
between LNS and LNS-VM groups for both K and phosphate were 0&#x000b7;0002 overall and differences
in the pre- and post-ART time periods were also highly significant (<xref ref-type="fig" rid="fig1">Fig. 1</xref>). In the LNS-VM arm values of electrolytes were found on average
to increase up to the time ART started and then reduce to baseline levels by the end of
follow-up whereas in the LNS arm average values changed little over follow-up time.<fig id="fig1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Changes in predicted mean serum electrolytes over time by trial arm, for an
individual who started antiretroviral therapy (ART) 3 weeks after recruitment. (a)
Phosphate: <italic>P</italic> values for differences between lipid-based nutritional
supplement (LNS) and lipid-based nutritional supplements fortified with vitamins and
minerals (LNS-VM) groups were 0&#x000b7;0002 overall, 0&#x000b7;008 pre-ART and 0&#x000b7;0003 post-ART.
Curves represent marginal predictions based on all available data for all patients and
are derived from piecewise cubic equations with random slopes and intercepts.
Prediction equations have different slopes pre- and post-starting ART. (b) K:
<italic>P</italic> values for differences between LNS and LNS-VM groups were 0&#x000b7;0002
overall, 0&#x000b7;0002 pre-ART and 0&#x000b7;004 post-ART. Curves represent marginal predictions
based on all available data for all patients and are derived from piecewise cubic
equations with random slopes and intercepts. Prediction equations have different
slopes pre- and post-starting ART. <inline-graphic xlink:href="S0007114517000721_inline1.jpg" mime-subtype="gif"/>, LNS; <inline-graphic xlink:href="S0007114517000721_inline2.jpg" mime-subtype="gif"/>,
LNS-VM.</p></caption><graphic xlink:href="S0007114517000721_fig1"/></fig>
</p><p>Mortality was higher among males, Tanzanians, those with oedema at baseline, those not on
tuberculosis medication at baseline, and increased with age, with higher C-reactive protein
(CRP), with lower CD4 cell count and with lower BMI at baseline (data presented by Woodd
<italic>et al</italic>.<sup>(</sup>
<xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup>). The current value of plasma electrolyte and the change from the previous
value showed significant interaction for phosphate analyses so the nine level categorical
analysis is presented; these interactions were not significant for K, so main effects are
presented (<xref ref-type="table" rid="tab4">Table 4</xref>). Once adjusted for factors
associated with mortality, there was some evidence overall (<italic>P</italic>=0&#x000b7;03,
phosphate, <italic>P</italic>=0&#x000b7;06 K) that time-varying electrolytes affected mortality
(<xref ref-type="table" rid="tab4">Table 4</xref>, <italic>n</italic> 9027 phosphate
measurements on 1588 participants, <italic>n</italic> 8709 K measurements on 1588
participants; median number of measurements in those dying was 3 (IQR 2, 5) and in those
completing follow-up was 8 (IQR 6, 9)). Compared with participants with stable measurements
around the mean, participants with electrolyte values which were not stable, had increased
hazard of mortality (<xref ref-type="table" rid="tab4">Table 4</xref>). Although there was
no evidence that the effect of serum electrolytes was modified by trial arm (<italic>P</italic>
<sub>for interaction</sub>&#x0003e;0&#x000b7;34), due to the LNS-VM arm containing electrolytes by
design, we <italic>a priori</italic> also examined the effect of changes in electrolytes
stratified by trial arm (online Supplementary Tables S4(a) and (b)); the estimates were
comparable to those in <xref ref-type="table" rid="tab4">Table 4</xref>. The effect of
changes in phosphate was statistically significant in both arms, but the magnitudes of the
adjusted hazard ratios tended to be greater in the LNS-VM than in the LNS arm. It should be
noted that the intervention had no overall effect on mortality<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup> and that the number of deaths in some electrolyte groups was small in these
analyses of separate trial arms.<table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Poisson regression models for time-varying serum electrolyte values associated with
mortality between referral for antiretroviral therapy (ART) and ART initiation
(Unadjusted and adjusted hazard ratios (HR) and 95 % confidence intervals)</p></caption><alternatives><graphic xlink:href="S0007114517000721_tab4"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Change from</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">Mortality rate/100 person-years</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Current values<xref ref-type="fn" rid="tab4fn1">*</xref>
</th><th align="left" rowspan="1" colspan="1">previous value<xref ref-type="fn" rid="tab4fn2">&#x02020;</xref>
</th><th align="center" rowspan="1" colspan="1">Deaths (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">100 person-years</th><th align="center" rowspan="1" colspan="1">HR<xref ref-type="fn" rid="tab4fn3">&#x02021;</xref>
</th><th align="center" rowspan="1" colspan="1">95 % CI</th><th align="center" rowspan="1" colspan="1">Unadjusted HR<xref ref-type="fn" rid="tab4fn3">&#x02021;</xref>
</th><th align="center" rowspan="1" colspan="1">95 % CI</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="center" rowspan="1" colspan="1">Adjusted HR<xref ref-type="fn" rid="tab4fn4">&#x000a7;</xref>
</th><th align="center" rowspan="1" colspan="1">95 % CI</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="12">Phosphate<xref ref-type="fn" rid="tab4fn5">||</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> Low</td><td align="left" rowspan="1" colspan="1">Decrease</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;34</td><td align="char" char="." rowspan="1" colspan="1">70</td><td align="char" char="," rowspan="1" colspan="1">47, 105</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;59</td><td align="char" char="," rowspan="1" colspan="1">2&#x000b7;15, 5&#x000b7;98</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;93</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;13, 3&#x000b7;32</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Low</td><td align="left" rowspan="1" colspan="1">No change</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;48</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="," rowspan="1" colspan="1">27, 65</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;82</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;06, 3&#x000b7;14</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;79</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;01, 3&#x000b7;17</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Low</td><td align="left" rowspan="1" colspan="1">Increase</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;02</td><td align="char" char="." rowspan="1" colspan="1">180</td><td align="char" char="," rowspan="1" colspan="1">68, 481</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13&#x000b7;01</td><td align="char" char="," rowspan="1" colspan="1">4&#x000b7;60, 36&#x000b7;75</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;09</td><td align="char" char="," rowspan="1" colspan="1">2&#x000b7;34, 21&#x000b7;54</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Middle</td><td align="left" rowspan="1" colspan="1">Decrease</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;35</td><td align="char" char="." rowspan="1" colspan="1">89</td><td align="char" char="," rowspan="1" colspan="1">63, 127</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;89</td><td align="char" char="," rowspan="1" colspan="1">3&#x000b7;04, 7&#x000b7;88</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;80</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;69, 4&#x000b7;67</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Middle</td><td align="left" rowspan="1" colspan="1">No change</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;67</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="," rowspan="1" colspan="1">17, 31</td><td align="center" rowspan="1" colspan="2">Ref.</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x0003c;0&#x000b7;001</td><td align="center" rowspan="1" colspan="2">Ref.</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x0003c;0&#x000b7;001</td></tr><tr><td align="left" rowspan="1" colspan="1"> Middle</td><td align="left" rowspan="1" colspan="1">Increase</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;28</td><td align="char" char="." rowspan="1" colspan="1">98</td><td align="char" char="," rowspan="1" colspan="1">67, 142</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;65</td><td align="char" char="," rowspan="1" colspan="1">2&#x000b7;82, 7&#x000b7;69</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;62</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;53, 4&#x000b7;49</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> High</td><td align="left" rowspan="1" colspan="1">Decrease</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;05</td><td align="char" char="." rowspan="1" colspan="1">107</td><td align="char" char="," rowspan="1" colspan="1">45, 258</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;55</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;77, 11&#x000b7;65</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;75</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;39, 10&#x000b7;12</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> High</td><td align="left" rowspan="1" colspan="1">No change</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;42</td><td align="char" char="." rowspan="1" colspan="1">33</td><td align="char" char="," rowspan="1" colspan="1">20, 56</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;43</td><td align="char" char="," rowspan="1" colspan="1">0&#x000b7;78, 2&#x000b7;65</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;34</td><td align="char" char="," rowspan="1" colspan="1">0&#x000b7;69, 2&#x000b7;61</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> High</td><td align="left" rowspan="1" colspan="1">Increase</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;39</td><td align="char" char="." rowspan="1" colspan="1">72</td><td align="char" char="," rowspan="1" colspan="1">50, 104</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;27</td><td align="char" char="," rowspan="1" colspan="1">2&#x000b7;00, 5&#x000b7;35</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;99</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;18, 3&#x000b7;35</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="12">K<xref ref-type="fn" rid="tab4fn6">&#x000b6;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> Low</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;91</td><td align="char" char="." rowspan="1" colspan="1">102</td><td align="char" char="," rowspan="1" colspan="1">83, 125</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;09</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;55, 2&#x000b7;83</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;26</td><td align="char" char="," rowspan="1" colspan="1">0&#x000b7;92, 1&#x000b7;73</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Middle</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." rowspan="1" colspan="1">104</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;80</td><td align="char" char="." rowspan="1" colspan="1">37</td><td align="char" char="," rowspan="1" colspan="1">31, 45</td><td align="center" rowspan="1" colspan="2">Ref.</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x0003c;0&#x000b7;001</td><td align="center" rowspan="1" colspan="2">Ref.</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;20</td></tr><tr><td align="left" rowspan="1" colspan="1"> High</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;79</td><td align="char" char="." rowspan="1" colspan="1">67</td><td align="char" char="," rowspan="1" colspan="1">52, 88</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;52</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;06, 2&#x000b7;17</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;32</td><td align="char" char="," rowspan="1" colspan="1">0&#x000b7;91, 1&#x000b7;92</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02013;</td><td align="left" rowspan="1" colspan="1">Decrease</td><td align="char" char="." rowspan="1" colspan="1">97</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;94</td><td align="char" char="." rowspan="1" colspan="1">103</td><td align="char" char="," rowspan="1" colspan="1">84, 126</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;72</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;98, 3&#x000b7;74</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;48</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;06, 2&#x000b7;07</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02013;</td><td align="left" rowspan="1" colspan="1">No change</td><td align="char" char="." rowspan="1" colspan="1">78</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;60</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="," rowspan="1" colspan="1">24, 37</td><td align="center" rowspan="1" colspan="2">Ref.</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x0003c;0&#x000b7;001</td><td align="center" rowspan="1" colspan="2">Ref.</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;06</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02013;</td><td align="left" rowspan="1" colspan="1">Increase</td><td align="char" char="." rowspan="1" colspan="1">73</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;91</td><td align="char" char="." rowspan="1" colspan="1">81</td><td align="char" char="," rowspan="1" colspan="1">64, 101</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;36</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;67, 3&#x000b7;34</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;30</td><td align="char" char="," rowspan="1" colspan="1">0&#x000b7;92, 1&#x000b7;85</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Ref., referent values.</p></fn><fn id="tab4fn1"><label>*</label><p>For phosphate low is 0&#x000b7;04&#x02013;0&#x000b7;96, middle is 0&#x000b7;97&#x02013;1&#x000b7;44, high is 1&#x000b7;45&#x02013;5&#x000b7;27. For K low
is 0&#x000b7;1&#x02013;3&#x000b7;63, middle is 3&#x000b7;63&#x02013;4&#x000b7;5 and high is 4&#x000b7;6&#x02013;10 mmol/l.</p></fn><fn id="tab4fn2"><label>&#x02020;</label><p>For serum phosphate daily changes were defined as: &#x0003c;&#x02212;0&#x000b7;02 a decrease,
(&#x02212;0&#x000b7;02, 0&#x000b7;02) no change and &#x0003e;0&#x000b7;02 increase&#x000b7; For K daily changes were defined
as &#x0003c;&#x02212;0&#x000b7;03 a decrease, (&#x02212;0&#x000b7;03, 0&#x000b7;03) no change and &#x0003e;0&#x000b7;03 an
increase.</p></fn><fn id="tab4fn3"><label>&#x02021;</label><p>A Lexis expansion for time was adjusted for in 4-week time bands, both pre-art and
post-art. Being on ART was also adjusted for.</p></fn><fn id="tab4fn4"><label>&#x000a7;</label><p>Adjusted for trial arm (lipid-based nutritional supplement or lipid-based
nutritional supplements fortified with vitamins and minerals), time band (as for
<xref ref-type="fn" rid="tab4fn3">&#x02021;</xref>), country, sex, age group (18&#x02013;29,
30&#x02013;39, 40&#x02013;49, &#x02265;50 years), baseline CD4 count (&#x0003c;50, 50&#x02013;99, 100&#x02013;199, &#x02265;200
cells/&#x003bc;l), BMI (continuous), baseline tuberculosis treatment (yes/no), baseline
oedema (yes/no), baseline C-reactive protein (&#x0003c;10, 10&#x02013;49, 50&#x02013;159, &#x02265;160
mg/l).</p></fn><fn id="tab4fn5"><label>||</label><p>
<italic>P</italic>
<sub>for interaction</sub> value between current level and change from previous
level unadjusted model=0&#x000b7;03, adjusted model=0&#x000b7;03.</p></fn><fn id="tab4fn6"><label>&#x000b6;</label><p>
<italic>P</italic>
<sub>for interaction</sub> value between current level and change from previous
level unadjusted model=0&#x000b7;85, adjusted model=0&#x000b7;47.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Our previous analysis of baseline serum electrolyte data and subsequent mortality in the
malnourished NUSTART cohort<sup>(</sup>
<xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> showed no significant effects of baseline serum phosphate or K on mortality to
12 weeks after starting ART but this finding differed from the significant mortality risk of
low phosphate at start of ART reported in a similar cohort of malnourished Zambians starting
ART<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>. Given these conflicting findings regarding electrolyte levels at the time of
treatment initiation, the present analysis extends these findings to time intervals both
before and after starting ART in order to give a fuller picture of the dynamic situation in
which serum electrolytes change over time under the influence of several factors: diet,
tissue catabolism or anabolism, ART and renal function. The values in the LNS group may
reflect the usual situation without provision of high levels of vitamins and minerals since,
even though LNS is not usually given, food intake increases as health and appetite improve
with ART<sup>(</sup>
<xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. The LNS-VM group shows the added effect of providing vitamins and minerals.
High levels of serum K were uncommon at both baseline and during the intervention whereas
high phosphate was common throughout, especially in the LNS-VM group. The level of phosphate
in the LNS-VM preparation was about twice the RNI and much lower than the tolerable upper
level<sup>(</sup>
<xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. Therefore the high incidence of above-normal serum phosphate suggests that
malnourished, HIV-infected adults have much lower metabolic capacity to handle this
electrolyte than do healthy individuals. In a small subset of the NUSTART Lusaka patients we
did find evidence of abnormal renal wasting of electrolytes which was improved in the LNS-VM
group by week 12<sup>(</sup>
<xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>. Renal wasting of electrolytes would be expected to result in abnormally low,
not high electrolytes. Unfortunately, we do not have data on renal electrolyte handling at
any time points between baseline and 12 weeks ART.</p><p>Important questions are whether transient changes in serum electrolytes resulted in any
adverse effects to the patients and whether relatively high intakes of electrolytes affected
the number of adverse events. The results suggest that changes in serum electrolytes between
visits, largely irrespective of the starting point and the direction of change, were more
strongly associated with mortality than were absolute electrolyte levels. The changes
appeared to have their greatest effects for phosphate, and high supplementary amounts of
electrolytes through LNS-VM treatment may have accentuated the effects. Labile serum
electrolyte levels support the idea of poor metabolic control among this malnourished
population with advanced HIV, and high supplementary electrolytes may further impair this
control. The lack of association between serum K and mortality may appear surprising. We
were able to examine only the effect (and showed no association) of above average values, as
the number of patients with abnormal, and in particular extremely abnormal values was low.</p><p>The study has several limitations. We are unable to comment on additional dietary sources
of electrolytes as detailed dietary intakes were not measured in the trial. In addition,
levels of phosphate in the supplements were analysed by the manufacturer which is a
potential limitation, although likely not a large one as the two supplements were clearly
different and the focus of the study was on patient metabolism, not intake. Although
randomisation and a large sample size should have ensured balance between trial arms and
reduced potential effects of residual confounding, in this observational investigation we
cannot estimate causal associations between serum electrolyte levels and mortality. It is
possible that electrolyte changes could also be a consequence of illness which leads to
increased mortality through another causal pathway. We adjusted for illness, as measured by
serum CRP and tuberculosis infection (treatment), although we know that some mortality could
be partially explained by undiagnosed tuberculosis infection among other causes. In
addition, by including electrolyte levels as a time-varying confounder we are making the
assumption that the effect of electrolytes on mortality is not modified by follow-up time.
An alternative formulation to investigate for time-modified confounding could be structural
equation models. As our follow-up time was relatively short, our assumption, and simpler
model, should be adequate. Finally, we were unable to assess for any time-varying influence
of CD4 cell count as this was only measured at baseline and end of study which, if it
influenced the relationship between electrolyte levels and mortality, could increase the
potential for residual confounding.</p><p>The main strength of our study was the large longitudinal sample size of serum electrolyte
values which were repeated at fairly regular intervals, weekly or fortnightly for most
participants. In addition, being able to compare within participants from referral until
after ART commenced provided valuable and clinically relevant information on changes over
time. We, however, cannot rule out that visit frequency and timing could have been related
in part to participant health, with both increases in frequency (unscheduled visits and
extra serum testing due to illness) and decreases in frequency (very ill leading to death)
occurring because of ill health. Given the large sample size, we would envisage that the
results are robust enough to any form of systematic bias. We have chosen to present results
combined over intervention groups partly because the intervention did not significantly
affect mortality, but also because we know that participant adherence to supplements was on
the low side, with only 39 % of participants consuming at least 75 % of their LNS sachets,
thus reducing differences in electrolyte intake<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. As we were not able to tell if adherence changed when the energetic dose
increased at 2 weeks from ART initiation, we are not able to infer if the decrease in serum
electrolyte levels post-ART could be partially explained by decreased dosing if participants
were unable to consume all of their LNS at the higher energy level or if it was truly due to
metabolic stabilisation or commencing ART.</p><p>Low serum phosphate is commonly seen in malnourished patients, both with and without HIV
infection, and is associated with poor outcomes<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>,</sup>
<xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>,</sup>
<xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>. Our analyses focused on electrolyte metabolism, not dietary intake other than
the differences between the LNS and LNS-VM preparations. However, dietary management of
these patients remains critical and the amounts of phosphate and other electrolytes which
should be provided in therapeutic diets for malnourished people in order to restore
metabolic stability, increase tissue deposition and avoid the refeeding syndrome or other
adverse effects is still under research<sup>(</sup>
<xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>. Based on our results, we recommend that future interventions to improve
nutritional status of malnourished HIV-infected patients should not include high doses of
electrolytes early after starting ART as malnourished HIV patients appear unable to handle
electrolytes, particularly phosphate, adequately. Once metabolism is stabilised and health
improves, both K and phosphate are needed for tissue deposition so should be provided in
adequate amounts.</p></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>The authors are grateful to the large clinical, laboratory and data teams involved in the
NUSTART trial in both Mwanza and Lusaka and to the study participants who donated their time
and samples.</p><p>This study was funded by European and Developing Countries Clinical Trials Partnership
grant no. IP.2009.33011.004; trial foods were prepared and supplied by Nutriset, Malauney,
France. Salary support for A. M. R. was provided by the Medical Research Council (MRC)
Tropical Epidemiology Group jointly funded under grant no. MR/K012126/1 by the UK MRC and
the UK Department for International Development (DFID) under the MRC/DFID Concordat
agreement and is also part of the EDCTP2 programme supported by the European Union. None of
the funders had any role in the design, conduct or interpretation of the study and decision
to publish results.</p><p>A. M. R. conducted the statistical analyses with input from S. L. W. S. F. drafted the
manuscript and was principal investigator for the NUSTART trial. D. C. H., J. R. K., H. F.,
G. P., L. K. and P. K. were involved in the design and interpretation of the NUSTART trial
including the component in this manuscript. All authors approved the final manuscript.</p><p>The authors declare that there are no conflicts of interest.</p></ack><sec sec-type="supplementary-material" id="sec5"><title>Supplementary material</title><supplementary-material content-type="local-data" id="S0007114517000721sup001"><p>For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0007114517000721.</p><media xlink:href="S0007114517000721sup001.docx" mimetype="application" mime-subtype="msword" orientation="portrait" id="d35e2811" position="anchor"><caption><p>click here to view supplementary material</p></caption></media></supplementary-material></sec><ref-list id="refs"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>E</given-names></name>, <name><surname>Spiegelman</surname><given-names>D</given-names></name>, <name><surname>Semu</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Nutritional status and
mortality among HIV-infected patients receiving antiretroviral therapy in
Tanzania</article-title>. <source>J Infect Dis</source>
<volume>204</volume>, <fpage>282</fpage>&#x02013;<lpage>290</lpage>.<pub-id pub-id-type="pmid">21673040</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal">
<name><surname>Koethe</surname><given-names>JR</given-names></name>, <name><surname>Lukusa</surname><given-names>A</given-names></name>, <name><surname>Giganti</surname><given-names>MJ</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Association between weight
gain and clinical outcomes among malnourished adults initiating antiretroviral therapy
in Lusaka, Zambia</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>53</volume>, <fpage>507</fpage>&#x02013;<lpage>513</lpage>.<pub-id pub-id-type="pmid">19730111</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal">
<name><surname>Gupta</surname><given-names>A</given-names></name>, <name><surname>Nadkarni</surname><given-names>G</given-names></name>, <name><surname>Yang</surname><given-names>WT</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Early mortality in adults
initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a
systematic review and meta-analysis</article-title>. <source>PLoS ONE</source>
<volume>6</volume>, <fpage>e28691</fpage>.<pub-id pub-id-type="pmid">22220193</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal">
<name><surname>Lawn</surname><given-names>SD</given-names></name>, <name><surname>Harries</surname><given-names>AD</given-names></name>, <name><surname>Anglaret</surname><given-names>X</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Early mortality among
adults accessing antiretroviral treatment programmes in sub-Saharan
Africa</article-title>. <source>AIDS</source>
<volume>22</volume>, <fpage>1897</fpage>&#x02013;<lpage>1908</lpage>.<pub-id pub-id-type="pmid">18784453</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal">
<name><surname>Dao</surname><given-names>CN</given-names></name>, <name><surname>Peters</surname><given-names>PJ</given-names></name>, <name><surname>Kiarie</surname><given-names>JN</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Hyponatremia,
hypochloremia, and hypoalbuminemia predict an increased risk of mortality during the
first year of antiretroviral therapy among HIV-infected Zambian and Kenyan
women</article-title>. <source>AIDS Res Hum Retroviruses</source>
<volume>27</volume>, <fpage>1149</fpage>&#x02013;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">21417949</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="other">
<name><surname>Ashworth</surname><given-names>A</given-names></name>, <name><surname>Khanum</surname><given-names>S</given-names></name>, <name><surname>Jackson</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2003</year>) Guidelines for the inpatient treatment of
severely malnourished children. <uri xlink:type="simple" xlink:href="http://www.who.int/nutrition/publications/guide_inpatient_text.pdf">http://www.who.int/nutrition/publications/guide_inpatient_text.pdf</uri>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal">
<name><surname>Heimburger</surname><given-names>DC</given-names></name>, <name><surname>Koethe</surname><given-names>JR</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Serum phosphate predicts
early mortality in adults starting antiretroviral therapy in Lusaka, Zambia: a
prospective cohort study</article-title>. <source>PLoS ONE</source>
<volume>5</volume>, <fpage>e10687</fpage>.<pub-id pub-id-type="pmid">20502700</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal">
<name><surname>Filteau</surname><given-names>S</given-names></name>, <name><surname>PrayGod</surname><given-names>G</given-names></name>, <name><surname>Kasonka</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Effects on mortality of a
nutritional intervention for malnourished HIV-infected adults referred for
antiretroviral therapy: a randomised controlled trial</article-title>. <source>BMC Med</source>
<volume>13</volume>, <fpage>17</fpage>.<pub-id pub-id-type="pmid">25630368</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal">
<name><surname>Friis</surname><given-names>H</given-names></name> (<year>2006</year>) <article-title>Micronutrient interventions and HIV infection:
a review of current evidence</article-title>. <source>Trop Med Int Health</source>
<volume>11</volume>, <fpage>1849</fpage>&#x02013;<lpage>1857</lpage>.<pub-id pub-id-type="pmid">17176350</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal">
<name><surname>Rehman</surname><given-names>AM</given-names></name>, <name><surname>Woodd</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Effects on anthropometry
and appetite of vitamins and minerals given in lipid nutritional supplements for
malnourished HIV-infected adults referred for antiretroviral therapy: results from the
NUSTART randomized controlled trial</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>68</volume>, <fpage>405</fpage>&#x02013;<lpage>412</lpage>.<pub-id pub-id-type="pmid">25501607</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal">
<name><surname>Woodd</surname><given-names>S</given-names></name>, <name><surname>Kelly</surname><given-names>P</given-names></name>, <name><surname>Koethe</surname><given-names>JR</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Risk factors for mortality
among malnourished HIV-infected adults eligible for antiretroviral
therapy</article-title>. <source>BMC Infect Dis</source>
<volume>16</volume>, <fpage>562</fpage>.<pub-id pub-id-type="pmid">27733134</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal">
<name><surname>Munkombwe</surname><given-names>D</given-names></name>, <name><surname>Muungo</surname><given-names>TL</given-names></name>, <name><surname>Michelo</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Lipid-based nutrient
supplements containing vitamins and minerals attenuate renal electrolyte loss in
HIV/AIDS patients starting antiretroviral therapy: a randomized controlled trial in
Zambia</article-title>. <source>Clinical Nutrition ESPEN</source>
<volume>13</volume>, <fpage>e8</fpage>&#x02013;<lpage>e14</lpage>.</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="book">
<collab>UK Department of Health</collab> (<year>1991</year>) <source>Dietary Reference
Values for Food Energy and Nutrients for the UK</source>.
<publisher-loc>London</publisher-loc>: <publisher-name>Department of
Health</publisher-name>.</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="book">
<collab>World Health Organization</collab> (<year>2007</year>) <source>WHO Case
Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological
Classification of HIV-Related Disease in Adults and Children</source>.
<publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>
<uri xlink:type="simple" xlink:href="http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf">http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf</uri>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="other">
<collab>UC Davis Clinical Trials Office</collab> (<year>2004</year>) Division of AIDS
table for grading the severity of adult and pediatric adverse events. <uri xlink:type="simple" xlink:href="http://ucdmc.ucdavis.edu/clinicaltrials/StudyTools/Documents/DAIDS_AE_GradingTable_FinalDec2004.pdf">http://ucdmc.ucdavis.edu/clinicaltrials/StudyTools/Documents/DAIDS_AE_GradingTable_FinalDec2004.pdf</uri>
(accessed November 2010).</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="book">
<name><surname>Tietz</surname><given-names>N</given-names></name> (<year>1995</year>) <source>Clinical Guide to Laboratory Tests</source>,
<edition>3rd ed</edition>
<publisher-loc>London</publisher-loc>: <publisher-name>WB
Saunders</publisher-name>.</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal">
<name><surname>Koethe</surname><given-names>JR</given-names></name>, <name><surname>Blevins</surname><given-names>M</given-names></name>, <name><surname>Bosire</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Self-reported dietary
intake and appetite predict early treatment outcome among low-BMI adults initiating HIV
treatment in sub-Saharan Africa</article-title>. <source>Public Health Nutr</source>
<volume>16</volume>, <fpage>549</fpage>&#x02013;<lpage>558</lpage>.<pub-id pub-id-type="pmid">22691872</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal">
<name><surname>Golden</surname><given-names>M</given-names></name> (<year>2009</year>) <article-title>Proposed recommended nutrient densities for
moderately malnourished children</article-title>. <source>Food Nutr Bull</source>
<volume>30</volume>, <fpage>S267</fpage>&#x02013;<lpage>S342</lpage>.<pub-id pub-id-type="pmid">19998863</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal">
<name><surname>Namusoke</surname><given-names>H</given-names></name>, <name><surname>Hother</surname><given-names>AL</given-names></name>, <name><surname>Rytter</surname><given-names>MJ</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Changes in plasma
phosphate during in-patient treatment of children with severe acute malnutrition: an
observational study in Uganda</article-title>. <source>Am J Clin Nutr</source>
<volume>103</volume>, <fpage>551</fpage>&#x02013;<lpage>558</lpage>.<pub-id pub-id-type="pmid">26739034</pub-id></mixed-citation></ref></ref-list></back></article>